NCT07176975 2026-02-27
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
Boehringer Ingelheim
Phase 1 Not yet recruiting
Boehringer Ingelheim
Tongji Hospital
Mirati Therapeutics Inc.
Boehringer Ingelheim
MedSIR
Autotelicbio
Zhujiang Hospital
Shanghai Tongji Hospital, Tongji University School of Medicine
Henan Cancer Hospital
Mabwell (Shanghai) Bioscience Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nanjing First Hospital, Nanjing Medical University
Fudan University
Fujian Cancer Hospital